NCT05224388View on ClinicalTrials.gov

Evaluating Dose Regimen of Intravenous Unfractionated Heparin and Low Molecular Weight Heparin in Critical Ill Patients Versus Critical Ill COVID-19 Patients Using Anti-Xa Levels.

CompletedOBSERVATIONAL

Enrollment

813

Participants

Timeline

Start Date

January 1, 2020

Primary Completion Date

August 31, 2021

Study Completion Date

September 15, 2022

Conditions

COVID-19Deep Vein ThrombosisAnticoagulants and Bleeding DisordersCritical Illness

Interventions

DRUG

Enoxaparin

Use of enoxaparin in either prophylactic dose regimen or therapeutic dose regimen

DRUG

Heparin

Use of heparin in either prophylactic dose regimen or therapeutic dose regimen

Trial Locations (1)

9000

Ghent University Hospital, Ghent

All Listed Sponsors

lead

University Hospital, Ghent

OTHER

NCT05224388 - Evaluating Dose Regimen of Intravenous Unfractionated Heparin and Low Molecular Weight Heparin in Critical Ill Patients Versus Critical Ill COVID-19 Patients Using Anti-Xa Levels. | Biotech Hunter | Biotech Hunter